Citigroup
TRVI icon

Citigroup’s Trevi Therapeutics TRVI Stock Holding History

Citigroup’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44M Sell
77,474
-22,475
-22% -$327K ﹤0.01% 3175
2026
Q1 		$1.19M Sell
99,949
-23,549
-19% -$264K ﹤0.01% 2999
2025
Q4 		$1.55M Buy
123,498
+96,585
+359% +$1.12M ﹤0.01% 2825
2025
Q3 		$246K Sell
26,913
-37,046
-58% -$278K ﹤0.01% 3909
2025
Q2 		$350K Buy
63,959
+10,065
+19% +$62.6K ﹤0.01% 3820
2025
Q1 		$339K Buy
53,894
+6,038
+13% +$28.8K ﹤0.01% 3886
2024
Q4 		$197K Buy
47,856
+5,232
+12% +$16.7K ﹤0.01% 4421
2024
Q3 		$142K Buy
42,624
+29,637
+228% +$88.1K ﹤0.01% 4585
2024
Q2 		$38.7K Buy
12,987
+4,284
+49% +$11.9K ﹤0.01% 4724
2024
Q1 		$30K Buy
8,703
+1,747
+25% +$3.9K ﹤0.01% 4892
2023
Q4 		$9.32K Buy
6,956
+6,913
+16,077% +$10.5K ﹤0.01% 5206
2023
Q3 		$94 Sell
43
-12,355
-100% -$27.9K ﹤0.01% 5422
2023
Q2 		$29.6K Buy
+12,398
New +$31.2K ﹤0.01% 4852
2022
Q3 		– Sell
-1,700
Closed -$5K – 6325
2022
Q2 		$5K Buy
+1,700
New +$4.18K ﹤0.01% 5633

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Citigroup's TRVI Position: Q2 2026 in Review

Citigroup reduced its Trevi Therapeutics (TRVI) stake by 22% in Q2 2026, selling an estimated $327K and leaving 77,474 shares worth $1.44M. The position accounts for ﹤0.01% of the portfolio, ranked #3175.

Citigroup first reported a position in TRVI in Q2 2022 and has held it in 14 quarters since. The position peaked at $1.55M in Q4 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Citigroup held 77,474 shares of Trevi Therapeutics worth $1.44M as of Q2 2026.
  • Citigroup sold 22,475 Trevi Therapeutics shares in Q2 2026, an estimated $327K.
  • Trevi Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3175 holding.
  • Citigroup first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Citigroup's Trevi Therapeutics position peaked at $1.55M in Q4 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.